The Lancet published an article on the MEDIOLA trial, a global study led by Basser Executive Director Susan Domchek, MD, which explored the use of a PARP inhibitor and immunotherapy as treatment options for BRCA-related breast cancer. The combination of olaparib and durvalumab showed promising antitumor activity.